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Abstract In Brazil, inclusion and exclusion of health
technologies within the Unified Health System (SUS) is the
responsibility of the National Committee for Health
Technology Incorporation (CONITEC). A recent Cochrane
systematic review demonstrated that intramuscular inter-
feron beta 1a (IFN-b-1a-IM) was inferior to the other beta
interferons (IFN-bs) for multiple sclerosis (MS). As a
result, CONITEC commissioned an analysis to review
possible disinvestment within SUS. The objective of this
paper is to describe the disinvestment process for IFN-b-
1a-IM in Brazil. The first assessment comprised a literature
review and mixed treatment comparison meta-analysis.
The outcome of interest was the proportion of relapse-free
patients in 2 years. This analysis confirmed the inferiority
of IFN-b-1a-IM. Following this, CONITEC recommended
disinvestment, with the decision sent for public consulta-
tion. More than 3000 contributions were made on CON-
ITEC’s webpage, most of them against the preliminary
decision. As a result, CONITEC commissioned a study to
assess the effectiveness of IFN-b-1a-IM among Brazilian
patients in routine clinical care. The second assessment
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involved an 11-year follow-up of a non-concurrent cohort
of 12,154 MS patients developed by deterministic-proba-
bilistic linkage of SUS administrative databases. The real-
world assessment further demonstrated that IFN-b-1a-IM
users had a statistically higher risk of treatment failure,
defined as treatment switching or relapse treatment or
death, with the assessment showing that IFN-b-1a-IM was
inferior to the other IFN-bs and to glatiramer acetate in
both direct and indirect analysis. In the drug ranking with
40,000 simulations, IFN-b-1a-IM was the worst option,
with a success rate of only 152/40,000. Following this,
CONITEC decided to exclude the intramuscular presenta-
tion of IFN-b from the current MS treatment guidelines,
giving patients who are currently on this treatment the
option of continuing until treatment failure. In conclusion,
we believe this is the first example of this new disinvest-
ment process in action, providing an exemplar for other
treatments in Brazil as well as other countries.
Key Points
In Brazil, the Unified Health System (SUS) provides
treatment for multiple sclerosis (MS), including three
pharmaceutical presentations of interferon beta
(IFN-b) as first-line treatment; evidence showing
inferiority of the intramuscular presentation impelled
the National Committee for Health Technology
Incorporation (CONITEC) to assess it for possible
disinvestment.
Direct and indirect meta-analysis (mixed treatment
comparison) with 11 trials showed intramuscular
IFN-b had the worst outcomes when compared to
other forms of IFN-b; however, this evidence was
not sufficient to convince more than 3000
contributors to the public consultation.
The meta-analysis combined with 11-year real-world
evidence from more than 12,000 Brazilian MS
patients showed that intramuscular IFN-b users had a
higher chance of treatment failure.
CONITEC decided to disinvest in the intramuscular
presentation of IFN-b on the basis of further
evidence; this was the first case of real-world
evidence guiding a disinvestment decision in Brazil.
1 Introduction
1.1 Background (General)
Since the creation of the National Committee for Health
Technology Incorporation (CONITEC, Comissa˜o Nacional
de Incorporac¸a˜o de Tecnologias no SUS) in the Brazilian
Public Health System (SUS, Sistema U´nico de Sau´de) in
2011 [1], Brazil has had a structured process for the
incorporation of different health technologies into SUS.
CONITEC includes representatives of the Brazilian Min-
istry of Health (MoH) and other public entities, the Federal
Council of Medicine (CFM, Conselho Federal de Medic-
ina) and patient representatives through the National
Health Council (CNS, Conselho Nacional de Sau´de). Up to
March 2017, CONITEC has recommended the incorpora-
tion of 197 health technologies and disinvestment of 43,
which have all been accepted by the Secretary of Science,
Technology and Strategic Inputs (SCTIE) of the MoH.
Disinvested technologies have comprised obsolete/aban-
doned and/or unsafe technologies. This terminology is
similar to that of other studies, acknowledging that many
different terms have been used to describe disinvestment,
making this a challenging area across countries [2–5].
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CONITEC procedures are established in law, and there
are internal regulations [6]. The Department of Manage-
ment and Incorporation of Health Technologies of the
SCTIE (DGITS/SCITE) forms the Executive Secretariat of
CONITEC, and is responsible for the management and
coordination of its activities, including formulating
investment and disinvestment requests. After formulating
or receiving a request for incorporation, disinvestment or
an alteration, whether from public bodies, private entities,
manufacturers, patient society or citizens, the DGITS/
SCTIE delegates the assessment of the evidence to its own
technicians or to a partner research centre that has no
conflict of interest with the assessed technology. After the
first analysis, CONITEC gathers to debate the preliminary
decision. This primary decision is available for public
consultation and also available as a patient information
leaflet with a complete health technology assessment report
[6].
The queries arising from the consultation are answered
by the same technicians or researchers that assessed the
technology. The deliberations are subsequently presented
to the members of the Commission, who either reach a final
recommendation or ask for more evidence. After a final
recommendation is made, the secretary of SCTIE evaluates
it and has its decision published in the official gazette.
Following this, the government has 180 days to initiate the
implementation process [6].
One such decision was the recent disinvestment of
intramuscular interferon beta 1a (IFN-b-1a-IM) for treat-
ment of multiple sclerosis (MS). To date, such procedures
and deliberations in Brazil have not been published.
Consequently, this paper presents a summary of the
detail disinvestment process of IFN-b-1a-IM for treatment
of MS in Brazil and CONITEC’s final recommendation
following identification as a potential disinvestment
opportunity. This builds on the recently agreed process for
disinvestment decisions in Brazil [7], as well as recent
systematic and other reviews in the area of disinvestment
[2–5]. We believe these activities will be of interest to
other governments and agencies seeking to instigate dis-
investment of less effective and/or less valued technologies
as they strive to provide universal healthcare with finite
resources.
1.2 Background to the Disinvestment Decision
In Brazil, the prevalence of MS ranges from 1.36/100,000
inhabitants to 27.2/100,000 inhabitants, depending on the
locality [8]. MS is primarily an autoimmune inflammatory
disorder of the brain and spinal cord in which focal lym-
phocytic infiltration leads to damage of myelin and axons
[9–11]. Studies show that, without treatment, MS leads to
irreversible disability in 15–20 years from diagnosis
[12–14]. The course of MS is highly varied and unpre-
dictable, and there are three main forms: relapsing-remit-
ting multiple sclerosis (RRMS), primary progressive
multiple sclerosis (PPMS), and secondary progressive
multiple sclerosis (SPMS). These forms can be active or
not active, and they are determined by clinical relapses or
magnetic resonance imaging (MRI) activity. There are also
two other classifications: clinically isolated syndrome
(CIS) and radiologically isolated syndrome (RIS) [15]. In
most patients, the disease is characterised initially by epi-
sodes of reversible neurological deficits (RRMS form),
which are often followed by progressive neurological
deterioration over time (SPMS form) [16].
The goal of the treatment of MS is disease remission,
defined as a complete absence of relapses, MRI evidence of
disease activity, or progression of disability [17]. Switching
disease-modifying treatment as soon as there is treatment
failure (defined as an occurrence of relapse, worsening of
disease activity, progress of the disability, or intolerability)
is highly recommended [18, 19]. SUS currently provides
interferon beta (IFN-b) free of charge for the treatment of
RRMS and SPMS forms of MS for patients meeting
guideline criteria, and until 2010, only three presentations
of IFN-b and glatiramer acetate were available to patients
compliant with the Brazilian clinical protocol for the
diagnosis and treatment of MS as first- or second-line
treatment (patients could start with either one of the
treatments and change to the other in the case of treatment
failure) [20]. Other treatments incurred 100% co-payment.
In 2010, natalizumab was made available as third-line
treatment, and in 2014, fingolimod was included for
natalizumab failures [21].
Despite more than 12 different disease-modifying ther-
apies currently available to treat MS, and more new
medicines expected soon [18], IFN-b and glatiramer acet-
ate [11] remain first-line options for patients in most clin-
ical settings, and are considered to be equally effective. In
Brazil, the updated guideline clearly states that IFN-b-1a-
IM, subcutaneous interferon beta 1a (IFN-b-1a-SC), sub-
cutaneous interferon beta 1b (IFN-b-1b-SC) and glatiramer
acetate are similarly effective, with their differences being
in their administration schedules and adverse event profiles
[21–24].
However, in 2015, a Cochrane systematic review [25]
showed that the IFN-b given once a week intramuscularly
(IFN-b-1a-IM) was inferior to other interferons given in a
more intense schedule subcutaneously. Because of this
evidence, the MoH in Brazil sought to evaluate the scien-
tific and clinical data regarding the effectiveness of IFN-b
for MS for analysis by the CONITEC. The applicant for
this potential disinvestment was the SCTIE of MoH, and
the first assessment team was the Health Technology
Assessment Centre of the Brazilian National Institute of
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Cardiology (NATS-INC), with additional information
requested from the SUS Collaborating Centre for Tech-
nology Assessment and Excellence in Health of the Federal
University of Minas Gerais (CCATES-UFMG).
When the MoH analysed the possibility to disinvest in
IFN-b-1a-IM following the Cochrane review being brought
to its attention [25], the objective was to evaluate the
effectiveness of this presentation compared with other first-
or second-line treatments (IFN-b-1a-SC, IFN-b-1b-SC and
glatiramer). Although the costs of each treatment are dif-
ferent (being between US$4763.81 and US$7394.20 for
subcutaneous IFN-b, US$6829.23 for intramuscular IFN-b
and US$6201.26 for glatiramer per patient per year)1,
improving cost-effectiveness was not the principal goal.
The potential use of less effective interventions for such a
severe and debilitating disease was the major driver for the
MoH to review potential disinvestment. However, reduced
effectiveness would impact on overall cost-effectiveness
when the cost of relapses, including further treatments,
were considered.
The first step undertaken in the disinvestment process
was the analysis of the efficacy of the different available
treatments, building on the Cochrane review [25]. Since the
Cochrane review compared 15 immunomodulators/im-
munosuppressants, a literature review of the efficacy and
safety of IFN-b was initially made. Since head-to-head
trials were scarce, the NATS-INC team opted to comple-
ment this approach with indirect comparisons, which
confirmed the inferiority of the IFN-b-1a-IM. Following
this, CONITEC decided to exclude this pharmaceutical
presentation from the national guideline, and sent the
report for public consultation. Within 20 days, more than
3000 comments had been submitted onto the CONITEC
webpage, most of them against the preliminary decision.
The controversy caused by the possible exclusion of IFN-
b-1a-IM made it necessary to more vigorously examine the
evidence for the performance of IFN-b in the Brazilian
population by means of a nationwide cohort analysis. This
formed the second part of the newly agreed disinvestment
process in Brazil [7].
2 Disinvestment Process
The process flow for the disinvestment process for IFN-b-
1a-IM is summarised in Fig. 1.
2.1 First Assessment
2.1.1 First Assessment: Methodology
NATS-INC personnel searched the references of the
Cochrane systematic review and performed a search on
March 2015 for new clinical trials in the Medline database,
using the following terms: ((Rebif[Title] OR Avo-
nex[Title]) OR Betaferon[Title]) OR Betaferon[Title] AND
(Clinical Trial[ptyp] AND ‘‘humans’’[MeSH Terms]). To
qualify for inclusion, studies had to be randomised con-
trolled trials comparing IFN-bs with each other or with
glatiramer acetate or with placebo in the treatment of
RRMS in adults. Clinical trials were excluded if they
evaluated IFN-b given in a dosing scheme different to
those recommended in the Brazilian clinical guideline
[20, 21].
The outcome of interest was the proportion of relapse-
free patients in 2 years. This usually is the primary out-
come of RRMS clinical trials and reflects the importance of
relapses to the increase in incapacity [25]. Risk of bias was
assessed using the Cochrane Collaboration risk of bias tool
[26] that comprises the evaluation of selection bias (se-
quence generation and allocation concealment), perfor-
mance bias (blinding of participants and personnel),
detection bias (blinding of the outcome assessment), attri-
tion bias (incomplete outcome data), and reporting bias
(selective outcome reporting).
We compared IFN-bs directly using a frequentist
approach, and compared them indirectly using a Bayesian
method. For the direct comparison, a meta-analysis was
performed between the trials, and we adopted a conserva-
tive approach using the Mantel–Haenszel method with
random effect model, with the 95% confidence interval
(CI) and data presented in decreasing order of magnitude of
effect, with the aid of Review Manager 5.0 software. For
the indirect comparison, the mixed treatment comparison
(MTC) was used, with the graphical interface MTC Jags
developed by the NATS-INC, available for free use at
R 3.3.3 packages (‘RcmdrPlugin.RMTCJags’). Among all
methods of indirect comparisons, this is the most versatile
and robust [27]. To improve robustness, glatiramer acetate
was included in the network of treatments. Data extraction
and analysis of measures of effect were performed by
intention to treat (ITT).
2.1.2 First Assessment: Results
We identified 11 trials: ten included in the Cochrane review
[23–25, 28–35] and one other [36] after searching Medline
(Table 1). Four studies [28, 29, 33, 34] and one other study
[31] were classified as presenting, respectively, unclear risk
and high risk of selection bias with respect to random
1 Brazilian Real (BRL) = US$0.3126563; Banco Central do Brasil,
28/04/2017.
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Fig. 1 Work plan for the disinvestment of IFN-b-1a-IM in Brazil.
CCATES-UFMG Collaborating Centre for Technology Assessment
and Excellence in Health of the Federal University of Minas Gerais,
CONITEC National Committee for Health Technology Incorporation,
DGITS/SCITE Department of Management and Incorporation of
Health Technologies of the SCTIE, HTA health technology assess-
ment, IFN-b-1a-IM intramuscular interferon beta 1a, NATS-INC
Health Technology Assessment Centre of the Brazilian National
Institute of Cardiology, SCTIE Secretary of Science, Technology and
Strategic Inputs
Table 1 Results of the studies
included in the meta-analysis
Study (author) Treatment No. Relapse free [n (%)]
The IFNB Multiple Sclerosis Study Group, [28] IFN-b-1b-SC 115 36 (31.3)
Placebo 112 18 (16.1)
Jacobs et al. [29] IFN-b-1a-IM 158 32 (20.3)
PRISMS Study Group [30] IFN-b-1a-SC 187 60 (32.1)
Placebo 187 30 (16.0)
Khan et al. [31] Placebo 33 1 (3.0)
IFN-b-1a-IM 40 4 (10.0)
IFN-b-1b-SC 41 11 (26.8)
Glatiramer 42 13 (31.0)
INCOMIN (Durelli et al.) [32] IFN-b-1b-SC 96 49 (51.0)
IFN-b-1a-IM 92 33 (35.9)
Koch-Henriksen et al. [33] IFN-b-1a-SC 143 64 (44.8)
IFN-b-1b-SC 158 77 (48.7)
Etemadifar et al. [34] IFN-b-1a-SC 30 17 (56.7)
IFN-b-1b-SC 30 13 (43.3)
IFN-b-1a-IM 30 6 (20.0)
EVIDENCE (Schwid et al.) [35] IFN-b-1a-SC 339 191 (56.3)
IFN-b-1a-IM 338 163 (48.2)
REGARD (Mikol et al.) [23] IFN-b-1a-SC 386 260 (67.4)
Glatiramer 378 246 (65.1)
BEYOND (O’Connor et al.) [24] IFN-b-1b-SC 897 520 (58.0)
Glatiramer 448 264 (58.9)
CombiRx (Lubin et al.) [36] IFN-b-1a-IM 250 185 (74.0)
Glatiramer 259 206 (79.5)
IFN-b interferon beta, IM intramuscular, SC subcutaneous
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sequence generation. As for allocation concealment, five
studies [23, 28, 29, 34, 35] and one other study [31] were
classified as presenting, respectively, unclear and high risk
of selection bias. In eight studies
[23, 24, 28–30, 32, 33, 35], pharmaceutical companies
either only financed the study or financed and participated
in the data analysis (Supplementary Material Figures 1A
and 2A, see the electronic supplementary material).
From the analysis, it is possible to observe the superi-
ority of IFN-b-1b-SC in relation to IFN-b-1a-IM [risk
ratio (RR) 1.58, 95% CI 1.17–2.13], and no significant
difference was observed among the other comparisons
(Fig. 2).
The indirect comparison shows superiority of IFN-b-1a-
SC, IFN-b-1b-SC and glatiramer compared to placebo.
Given the probability distribution characteristic of the odds
Fig. 2 Forest plots of direct comparison meta-analysis of the
proportion of patients relapse-free after 2 years of treatment: a IFN-
b-1a-SC vs IFN-b-1a-IM; b IFN-b-1b-SC vs IFN-b-1a-SC; c IFN-b-
1b-SC vs IFN-b-1a-IM. CI confidence interval, IFN-b interferon beta,
IM intramuscular, SC subcutaneous
Fig. 3 a Network of treatment comparisons and b forest plot
depicting odds ratio (OR) of indirect comparisons with corresponding
upper (U) and lower (L) credibility intervals (CIr). 1 = placebo;
2 = IFN-b-1a-SC; 3 = IFN-b-1b-SC; 4 = IFN-b-1a-IM; 5 = glati-
ramer acetate. IFN-b interferon beta, IM intramuscular, SC
subcutaneous
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ratio comparison, where the probability of the outcome is
greater around the central measure of the credibility
interval, the data suggest that IFN-b-1a-IM is superior to
placebo, and IFN-b-1a-SC and IFN-b-1b-SC are superior
to IFN-b-1a-IM (Fig. 3 and Supplementary Material Fig-
ures 3A and 4A).
A total of 40,000 simulations were carried out to esti-
mate drug rankings. The treatment with the highest success
rate was IFN-b-1a-SC, with a 43% success rate, or the best
option in 17,200 of the 40,000 simulations; glatiramer
acetate was the drug with the second highest success rate.
Among the IFN-bs, IFN-b-1b-SC was the second best
option in most of the simulations (7804/40,000) and the
worse option was IFN-b-1a-IM, with a success rate of only
152/40,000.
Considering the results, CONITEC recommended that
the findings be made available in a public consultation,
with the initial recommendation to disinvest in IFN-b-1a-
IM for the treatment of MS in the SUS guidance, due to its
inferiority in relation to the other IFN-bs.
2.2 Public Consultation
From September 7 to October 10, 2015, more than 3000
comments were received from the public consultation.
Most of them brought reports and lawsuits for the main-
tenance of IFN-b-1a-IM and its indication in SUS, arguing
that its possible withdrawal would be harmful to those who
were already on this IFN-b and were getting some benefit.
However, such claims did not provide adequate justifica-
tion or scientific evidence for continued funding. The
comments raised other issues favourable to the use of IFN-
b-1a-IM. These included being the medicine of choice in
pregnancy, good response of the drug (with reduction of
outbreaks and that its exchange would probably trigger
outbreaks), and better convenience of use (adherence) and
quality of life (for being administered intramuscularly once
a week).
Regarding these issues:
1. For the use of IFN-b-1a-IM in pregnancy, according to
the current recommendations of the current Brazilian
guideline, there is no IFN-b of choice for use during
this period, and it is recommended not to use
immunomodulators, because they have an unfavour-
able safety profile during pregnancy, and its use is
restricted to cases in which the clinical evolution of the
disease has been unfavourable [21]. Similarly, accord-
ing to the current text of the package leaflet of IFN-b-
1a-IM, discontinuation of treatment is the current
recommendation, since available data also indicate that
there may be an increased risk of spontaneous
abortion.
2. There is no robust evidence to support that there will
be harm to the patient if there is substitution of IFN-b-
1a-IM for another IFN-b.
3. There is also no robust evidence to prove greater
adherence to IFN-b-1a-IM and its consequences in a
review of the scientific literature.
After the public consultation, the results were again
discussed by members of CONITEC on October 10, 2015.
Following this, given the content of the public consultation
(mostly contrary to the preliminary recommendation for
exclusion), the Commission chose to seek more informa-
tion, including a new study on the effectiveness of the IFN-
bs in the real-world to enhance the robustness of any final
recommendation.
2.3 Second Assessment: Real-World Study
2.3.1 Second Assessment: Methodology
CCATES-UFMG personnel developed a national non-
concurrent open cohort study including adult RRMS
patients (IDC-10 G35) who were treated with IFN-bs in
Brazil from 1/1/2000 to 12/31/2010. The follow-up time
was from 1/1/2000 to 12/31/2010, consequently, covering
11 years. As previously mentioned, during this period only
IFN-bs and glatiramer acetate were available through the
SUS, and in the case of treatment failure, patients were
allowed to switch among them.
This cohort was developed by deterministic-probabilis-
tic linkage of the following SUS administrative databases:
Hospital Information System (SIH), Ambulatory Informa-
tion System (SIA), and Mortality Information System
(SIM) [28, 29]. The variables used for linkage were name,
name of the mother, date of birth, and the individual tax-
payer registration number. IFN-b is dispensed on a
monthly basis. The entry date was the date of the first drug
dispensed. For the evaluation of effectiveness, the event
used for survival analysis was treatment failure, identified
by treatment switching or relapse treatment or death,
whichever occurred first. Patients were allowed 3 consec-
utive months without medicine until they switched drugs.
The date of the last registry of drug dispensing was entered
if patients abandoned their treatment or interrupted their
treatment for 4 or more months (censored). Right censoring
was established on 12/31/2010 (end of follow-up).
Patients were analysed according to the IFN-b at study
entry. For the evaluation of effectiveness, we performed
two sensitivity analyses. In the first one, we adopted a ‘new
user’ design by excluding patients who started therapy
between 1/1/2000 and 12/31/2001. In the second, we did
not impose a time limit without a dispensing registry for
event assignment, that is, patients were not censored for
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abandonment if they returned to the index IFN-b or swit-
ched drugs at any time after interrupting their first treat-
ment. If they did not return to treatment, they were
censored for loss to follow-up.
For treatment persistence, the event used for survival
analysis was treatment switching, treatment abandonment
or treatment interruption, whichever occurred first. Patients
were censored at the date of death or on 12/31/2010. One-
year and 2-year treatment persistence were calculated by
dividing the number of patients still on their index IFN-b
by the number of patients with at least 12 or 24 months of
follow-up.
We calculated the frequency distributions for the cate-
gorical variables, and the mean and standard deviation
(SD) for the continuous variables. Student’s t test was used
to assess differences between the means of the two groups,
and the chi-square test was used to evaluate differences in
frequencies. We analysed the influence of the index IFN-b
and of each descriptive variable in treatment survival using
univariate analysis and evaluated their association with
treatment failure. The Kaplan–Meier method was used to
estimate the cumulative probability of survival. The dif-
ferent survival curves were compared using the log-rank
test. The influence of the index IFN-b in the occurrence of
treatment failure was also assessed using the Cox
proportional hazards model and the Wald test. The hazard
ratio (HR) for progression to the event was calculated
considering a 95% CI. Statistical analysis was performed
using ‘‘R’’ version 3.1.1 (R Foundation for Statistical
Computing) and SPSS version 17 (SPSS Inc., Chicago,
USA).
2.3.2 Second Assessment: Interferon Beta Real-World
Performance
From 18,358 identified patients, the following were
excluded: 674 patients for being younger than 18 years old
at the start of treatment; 3183 patients with less than six
procedures for the treatment of MS in the hospital or
ambulatory databases; 2176 for having started treatment
with glatiramer acetate; and 166 for having started treat-
ment with azathioprine.
Of the 12,154 included patients, the majority started
treatment with IFN-b-1a-SC (45.7%); followed by IFN-b-
1b-SC (27.7%) and IFN-b-1a-IM (26.5%). In all groups,
most of the patients were female and resided in the
Southeast of the country when they entered the cohort.
Although the groups statistically differed in their mean age
at study entry, the difference was not considered clinically
important (Table 2).
Table 2 Baseline
characteristics of Brazilian
patients with relapsing-
remitting multiple sclerosis
included in the study,
2000–2010
Variable IFN-b-1a-SC IFN-b-1b-SC IFN-b-1a-IM
n = 5557 n = 3372 n = 3225
Mean age, years± SDa 39.0± 11.4 39.3± 11.1 38.4± 11.4
Age group, n (%)
18–29 1307 (23.5) 747 (22.2) 811 (25.1)
30–39 1591 (28.6) 959 (28.4) 975 (30.2)
40–49 1625 (29.2) 1065 (31.6) 880 (27.3)
50–59 815 (14.7) 482 (14.3) 433 (13.4)
60? 219 (3.9) 119 (3.5) 126 (3.9)
Sex, female, n (%)b 4037 (72.6) 2404 (71.3) 2444 (75.8)
Geographic region of residence, n (%)
North 114 (2.0) 41 (0.9) 15 (0.4)
Northeast 867 (15.0) 374 (10.6) 277 (8.4)
Central-West 554 (10.5) 349 (11.0) 284 (8.8)
South 919 (16.5) 651 (19.9) 711 (22.3)
Southeast 3103 (56.0) 1957 (57.6) 1938 (60.2)
Calendar period of cohort entry, n (%)
2000–2004 2716 (44.8) 1480 (39.4) 724 (19.3)
2005–2010 2811 (55.2) 1892 (60.6) 2501 (80.7)
IFN-b interferon beta, IM intramuscular, SC subcutaneous, SD standard deviation
at test: IFN-b-1a-IM vs IFN-b-1b-SC, p = 0.0024; IFN-b-1a-IM vs IFN-b-1a-SC, p = 0.0217; IFN-b-1b-
SC vs IFN-b-1a-SC, p = 0.2928
bChi-square: IFN-b-1a-IM vs IFN-b-1b-SC, p = 0.000036; IFN-b-1a-IM vs IFN-b-1a-SC, p = 0.001275;
IFN-b-1b-SC vs IFN-b-1a-SC, p = 0.166474
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The analysis of the Kaplan–Meier curves for IFN-bs
revealed that IFN-b-1a-IM is inferior when compared to
the others (log-rank p\0.0001) (Fig. 4). The median time
to treatment failure was 47 months (95% CI 44–52) for
IFN-b-1a-IM, 69 months (95% CI 64–76) for IFN-b-1a-
SC, and 73 months (95% CI 66–84) for IFN-b-1b-SC
(p\0.0001 for both comparisons intramuscular vs
subcutaneous).
Univariate analysis revealed that the use of IFN-b-1a-
IM increased the risk of treatment failure (HR 1.381, 95%
CI 1.292–1.475; p\0.001), while the use of both subcu-
taneous IFN-bs had a protective effect (reference group 1a:
HR 0.864, 95% CI 0.814–0.917; 1b: HR 0.887, 95% CI
0.829–0.949; p\0.001). Both sensitivity analyses revealed
similar results to the main analysis (Supplementary Mate-
rial Figures 5A and 6A).
Persistence analysis revealed that a lower proportion of
patients who started treatment with intramuscular IFN-b
remained in the same treatment at 1 and 2 years from the
start of treatment compared with patients using either
subcutaneous IFN-b. There was no statistically significant
difference between the subcutaneous presentations
(Table 3).
The limitations of these results lie in the fact they were
extracted from administrative databases not created for
clinical outcomes assessment; consequently, we did not
have patient-level variables available, such as MRI results.
In addition, we believe that many cases of relapses and
adverse events were not registered in SUS databases
because some patients were treated in private clinics or
hospitals. To overcome this, we chose to use the composite
event of treatment failure capturing treatment switching
that, as indicated in the clinical protocol, happens in cases
of relapse, intolerance or adverse reaction [21].
2.4 Final Decision
This evidence was presented to the members of CONITEC
on May 4, 2016. The performance assessment ruled out for
the majority of the members the option to keep the IFN-b-
1a-IM in the guideline as it is. The possibility to restrict the
use of this medicine to patients non-adherent to treatment
with the other IFN-bs was debated, but the option to offer a
less effective medicine to patients as second-line was
firmly rejected.
Next, members debated the implications of full with-
drawal of this medicine. The first point raised by one of the
members of CONITEC was that by excluding this intra-
muscular IFN-b, the Commission was not removing a
Fig. 4 Kaplan–Meier curves depicting time to treatment failure,
defined as treatment switching, relapse or death for IFN-b-1a-SC,
IFN-b-1b-SC and IFN-b-1a-IM. IFN-b interferon beta, IM intramus-
cular, SC subcutaneous, S(t) survival function
Table 3 Twelve and
24 months’ persistence in index
IFN-b of the Brazilian patients
with relapsing-remitting
multiple sclerosis included in
the study, 2000–2010
Time period IFN-b-1a-SC IFN-b-1b-SC IFN-b-1a-IM
12 months
Persistent 4051 (76.6) 2432 (77.4) 2092 (71.6)
Total non-persistent 1235 709 828
Treatment switching 774 (62.7) 455 (64.2) 593 (71.6)
Treatment abandonment 457 (37.0) 253 (35.7) 234 (28.3)
Treatment interruption 4 (0.3) 1 (0.1) 1 (0.1)
24 months
Persistent 2864 (59.8) 1661 (60.5) 1244 (53.3)
Total non-persistent 1,929 1085 1092
Treatment switching 1139 (59.0) 676 (62.3) 751 (68.8)
Treatment abandonment 786 (40.7) 407 (37.5) 341 (34.2)
Treatment interruption 4 (0.2) 2 (0.2) 0 (0.0)
Values are shown are n (%)
Chi-square for both time periods: IFN-b-1a-IM vs IFN-b-1b-SC, p\0.0001; IFN-b-1a-IM vs IFN-b-1a-SC,
p\0.0001; IFN-b-1b-SC vs IFN-b-1a-SC, p[0.05
IFN-b interferon beta, IM intramuscular, SC subcutaneous
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treatment option from patients, since the active ingredient
would still be available in subcutaneous presentations. This
line of thought was followed by the majority of the
members except by those closely related to the health
authorities of the States in Brazil, who are responsible for
dispensing IFN-b and all other high-cost drugs.
The major concern was that patients would go to court
against the health authorities of the States in order to keep
their treatment and the objective of offering the best pos-
sible options to patients would be lost, with this option
increasingly used in Brazil to access technologies currently
not funded [37]. To address this issue, Commission
members decided to exclude the intramuscular presentation
of IFN-b from the guideline, but give patients who are
currently on this treatment the option of continuing until
treatment failure. The SCTIE agreed with the decision,
which was published in the official gazette on June 8, 2016
[38].
3 Overview of Disinvestment Process
IFN-b-1b-SC was the first treatment approved by the Food
and Drug Administration in the USA for RRMS in 1993,
followed by IFN-b-1a-IM in 1996, and by IFN-b-1a-SC in
2002, all of them with orphan drug designations [39]. In
Brazil, these drugs were licensed, respectively, in 1996,
1999, and 1996, and were subsequently incorporated into
SUS in 2001 [40], that is, 10 years before the creation of
CONITEC and the adoption of a formal health technology
assessment process [6].
The reassessment of these medicines occurred 15 years
after their incorporation, as appreciably more evidence
became available. The meta-analysis of randomised con-
trolled trials showed that IFN-b-1a-IM may have a success
rate similar to placebo, which led to the preliminary rec-
ommendation of exclusion of this pharmaceutical presen-
tation. However, this decision was heavily contested in the
public consultation. This may have been influenced by a
number of MS patient advocacy organisations (PAOs).
However, it is difficult to comment further since many of
these PAOs do not explicitly declare conflicts of interest on
their websites/online pages.
Despite the similar content of most comments in this
particular case, public consultation was, and has been, an
important tool for citizen participation. In this assessment
process, additional information regarding adherence to
treatment and safety were further investigated after these
points had been raised by public consultation. Even with
this new evidence showing that intramuscular IFN-b is not
as effective and safe as the other available treatments, and
does not improve patient adherence, the intensity of the
comments in the public consultation led the members of
CONITEC to commission a performance assessment to
explore the outcomes of the IFN-bs in the Brazilian pop-
ulation in more detail.
The need for a greater theoretical basis for divestment
than for investment has already been debated [41], and is
one of the many challenges for disinvestment initiatives
worldwide. In Brazil, disinvestment decisions are priori-
tised to occur after the study of the effectiveness of the
biomedical interventions in the Brazilian population. This
was established as a way to overcome concerns with ran-
domised controlled trials in terms of their lack of external
validity, and to reveal to society the real value of a tech-
nology, thus providing more convincing and robust evi-
dence [7].
The negative side of this approach is the time needed to
generate the evidence and the timing of the decisions.
Studying the performance of health technologies in the real
world takes time and resources, both of which may hamper
disinvestment decisions, as seen in other disinvestment
attempts worldwide [2]. This motivated CONITEC to
embrace a wider strategy in which prioritised technologies
will be assessed for performance for continued investment,
probably using partner research centres and funds already
available for research of interest to SUS.
Cost constraints have been the most common drivers of
disinvestment attempts [3]. In the present case, cost-ef-
fectiveness was not an immediate issue, as CONITEC
members were interested in assuring that RRMS patients
were getting the most effective treatment. We believe that a
cost-effectiveness analysis would not be necessary, since
all options are already available, that is, patients using
intramuscular IFN-b would change to either subcutaneous
presentation, which were considered cost-effective in the
first place. In the report sent to public consultation, it was
explained that the preliminary decision to disinvest in
intramuscular IFN-b was taken ‘‘due to its inferiority in
relation to the other IFN-b, despite its lower current cost.’’
This statement sends the message that saving money is not
a key point for the MoH in this case, which probably
avoided an even greater commotion in the public consul-
tation. This is in accordance with a recent systematic
review of 15 disinvestment programmes/experiences from
eight countries where efficacy was the most important
criterion for identification, prioritisation and assessment of
technologies for disinvestment, followed by economics [3].
Other approaches and processes appear similar [2, 4, 5].
Our process builds on this with additional investigation
with real-world evidence [7].
Our findings are in agreement with those of the Cana-
dian Drug Expert Committee from the Canadian Agency
for Drugs and Technologies in Health (CADTH), which
considered IFN-b-1b-SC cost-effective and therefore rec-
ommend its use as the initial pharmacotherapy of choice
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for the treatment of RRMS. When compared to placebo,
both IFN-b-1b-SC and IFN-b-1a-SC produced the same
annual rate of relapse; however, IFN-b-1a-SC had a higher
cost. For the same outcome, IFN-b-1a-IM was considered
less effective when compared directly and indirectly to
both subcutaneous forms [42].
In 2002, the National Institute for Health and Care
Excellence (NICE) issued a technology appraisal not rec-
ommending the use of either IFN-b or glatiramer acetate
for RRMS [43]. Although no IFN-b was considered a cost-
effective option, IFN-b-1b-SC was seen as the most cost-
effective among them [43]. In the same year, the UK
Department of Health produced a risk-sharing scheme to
supply the four medicines at a reasonable cost-effective
price within the UK National Health System, with the
initial results published in 2009 again suggesting limited
effectiveness, with a suggestion of outcomes worse than
the untreated comparator group [44, 45]. However, the
results of 6 years of follow-up of patients participating in
the risk-sharing scheme, published in May 2015, revealed
that IFN-b (altogether) and glatiramer acetate are cost-ef-
fective options, enhanced by including data sets from
British Columbia, supporting the decision of CONITEC to
continue to fund certain IFN-bs [46].
Some months after the MoH decision to disinvest in
intramuscular IFN-b, the company announced the licensing
of its pegylated version in the country. It is interesting to
note that this medicine gained access to the Brazilian
market, and to many others, after having performed better
than placebo [47]. In 2013, IFN-b-1a-IM was the medicine
with the second highest sales worldwide among treatments
for MS. IFN-b-1b-SC and IFN-b-1a-SC were fifth and
seventh, respectively [48]. According to an IMS health
report, MS medicines as a group represented the eighth
largest drug spend in the USA in 2015 [49]. This report
also foresaw that injectable treatment revenues would fall
in the coming years in the USA [49], which will probably
also happen in Brazil where fingolimod for second-line
treatment (after IFN-b or glatiramer failures) and teri-
flunomide as first-line treatment were incorporated in the
first months of 2017 [50, 51]. Interestingly, in Brazil in
September 2015, Bio-Manguinhos, a biologics plant of the
MoH funding Fundac¸a˜o Oswaldo Cruz (Fiocruz), signed a
technology transfer agreement with Merck and Bionovis to
produce IFN-b-1a-IM [52], which was the IFN-b initial
treatment between 2000 and 2010.
As with suggestions for potential investment in Brazil,
proposals for disinvestment can be suggested by pharma-
ceutical companies as well as other stakeholders. However,
we believe it is generally unlikely that a pharmaceutical
company would normally submit a disinvestment request
to CONITEC for a medicine within a treatment group. This
would generally only be possible with a ‘one in, one out’
policy, in which only full withdrawal and substitutions
were possible. This typically only takes place within
countries once generics become available in a class, or
related class, to stop the prescribing of a more expensive
patented product, without compromising care [5, 53–56].
This could also represent a change in the ‘add-on’ (with
escalating prices) paradigm of new more effective patented
technologies in a class, which can be a concern to health
authorities, as seen for instance with new cancer medicines
[57–60].
4 Conclusions
This was the first case of a disinvestment decision in Brazil
based on effectiveness using different approaches, includ-
ing real-world data, following the adoption of the national
guideline for technology performance assessment in Brazil
[7, 61]. The decision will be fully implemented after the
update of the clinical guideline for MS. Until this occurs,
the disinvestment decision based on the various studies
conducted, including meta-analyses and real-world studies,
remains at the mercy of revocation requests.
We hope this process in Brazil will be of interest to
other countries, especially those providing universal
healthcare, as they seek to better manage both investment
and disinvestment decisions with finite resources
[5, 60, 62]. Future research will concentrate on evaluating
the challenges of this disinvestment process, including the
possible rise in judicial requests in Brazil and their costs,
building on previous cases [37].
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